Cargando…
Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States
BACKGROUND: Oral semaglutide is the first orally administered glucagon-like peptide-1 receptor agonist (GLP-1RA) approved by the FDA. Clinical trials found that oral semaglutide 14 mg had a greater reduction in hemoglobin A1c (A1c) compared with empagliflozin 25 mg and sitagliptin 100 mg and was non...
Autores principales: | Cui, Jiayu, Klepser, Donald G, McAdam-Marx, Carrie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391238/ https://www.ncbi.nlm.nih.gov/pubmed/34185562 http://dx.doi.org/10.18553/jmcp.2021.27.7.840 |
Ejemplares similares
-
Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States
por: Zhang, Xiaotong, et al.
Publicado: (2023) -
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States
por: Hunt, Barnaby, et al.
Publicado: (2019) -
Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
por: Sandhu, Hera, et al.
Publicado: (2023) -
Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States
por: Lu, Yuan, et al.
Publicado: (2022) -
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
por: Malkin, Samuel J. P., et al.
Publicado: (2022)